Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15794946rdf:typepubmed:Citationlld:pubmed
pubmed-article:15794946lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:15794946lifeskim:mentionsumls-concept:C0001492lld:lifeskim
pubmed-article:15794946lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:15794946lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:15794946lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:15794946lifeskim:mentionsumls-concept:C0279023lld:lifeskim
pubmed-article:15794946lifeskim:mentionsumls-concept:C0596235lld:lifeskim
pubmed-article:15794946pubmed:issue8lld:pubmed
pubmed-article:15794946pubmed:dateCreated2005-3-29lld:pubmed
pubmed-article:15794946pubmed:abstractTextAdenylate cyclase (EC 4.6.1.1) type 9 (AC9) activity has been shown to be inhibited by PMA activation of novel protein kinase C (nPKC) isoforms. In the current study the effect on AC9 activity of activating PKC in physiological relevant manner was examined. Contrary to the anticipated inhibitory effect of activating PKCs through Gq-coupled receptors, activation of transiently expressed Gq-coupled serotonin 5-HT2A or muscarinic M5 receptors resulted in the potentiation of isoproterenol-stimulated cyclic AMP accumulation in HEK293 cells stably expressing AC9 (HEK-AC9). Consistent with Gq-mediated activation of PKC, the addition of the PKC inhibitor bisindolylmaleimide further potentiated isoproterenol-stimulated cyclic AMP accumulation. Expression of a constitutively active mutant of Galphaq in HEK-AC9 cells also produced an enhancement in basal and isoproterenol-stimulated cyclic AMP accumulation. We also examined the role of Galphaq-mediated release of intracellular Ca2+ on the observed potentiation of AC9 activity, by depleting intracellular Ca2+ stores with thapsigargin. In Ca2+-depleted HEK-AC9 cells, activation of transiently expressed M5 receptors resulted in inhibition of isoproterenol-stimulated cyclic AMP accumulation that was blocked by bisindolylmaleimide, indicating that M5 potentiation of AC9 activity requires Ca2+. This prompted us to examine the effects of the calmodulin antagonist W7 and the Ca2+/calmodulin-dependent kinase II (CaMK II) inhibitor KN-93. Pretreating cells with W7 and KN-93 significantly inhibited M5-mediated potentiation of isoproterenol-stimulated cyclic AMP accumulation in HEK-AC9 cells, suggesting that Galphaq potentiation of AC9 activity involves Ca2+/calmodulin and CaMK II. This data provides evidence for Ca2+-mediated potentiation of AC9 activity.lld:pubmed
pubmed-article:15794946pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:languageenglld:pubmed
pubmed-article:15794946pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:citationSubsetIMlld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15794946pubmed:statusMEDLINElld:pubmed
pubmed-article:15794946pubmed:monthAprlld:pubmed
pubmed-article:15794946pubmed:issn0006-2952lld:pubmed
pubmed-article:15794946pubmed:authorpubmed-author:WattsVal JVJlld:pubmed
pubmed-article:15794946pubmed:authorpubmed-author:CumbayMedhane...lld:pubmed
pubmed-article:15794946pubmed:issnTypePrintlld:pubmed
pubmed-article:15794946pubmed:day15lld:pubmed
pubmed-article:15794946pubmed:volume69lld:pubmed
pubmed-article:15794946pubmed:ownerNLMlld:pubmed
pubmed-article:15794946pubmed:authorsCompleteYlld:pubmed
pubmed-article:15794946pubmed:pagination1247-56lld:pubmed
pubmed-article:15794946pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:meshHeadingpubmed-meshheading:15794946...lld:pubmed
pubmed-article:15794946pubmed:year2005lld:pubmed
pubmed-article:15794946pubmed:articleTitleGalphaq potentiation of adenylate cyclase type 9 activity through a Ca2+/calmodulin-dependent pathway.lld:pubmed
pubmed-article:15794946pubmed:affiliationPurdue University, Department of Medicinal Chemistry and Molecular Pharmacology, 575 Stadium Mall Drive, West Lafayette, IN 47907-2051, USA.lld:pubmed
pubmed-article:15794946pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15794946pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
entrez-gene:2776entrezgene:pubmedpubmed-article:15794946lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15794946lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15794946lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15794946lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15794946lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15794946lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15794946lld:pubmed